BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14977842)

  • 1. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients.
    Pierga JY; Bonneton C; Vincent-Salomon A; de Cremoux P; Nos C; Blin N; Pouillart P; Thiery JP; Magdelénat H
    Clin Cancer Res; 2004 Feb; 10(4):1392-400. PubMed ID: 14977842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.
    Pierga JY; Deneux L; Bonneton C; Vincent-Salomon A; Nos C; Anract P; Magdelénat H; Pouillart P; Thiery JP
    Int J Biol Markers; 2004; 19(1):23-31. PubMed ID: 15077923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
    Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
    J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in bone marrow and peripheral blood of patients with metastatic breast cancer.
    Bischoff J; Rosenberg R; Dahm M; Janni W; Gutschow K
    Recent Results Cancer Res; 2003; 162():135-40. PubMed ID: 12790327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.
    Effenberger KE; Borgen E; Eulenburg CZ; Bartkowiak K; Grosser A; Synnestvedt M; Kaaresen R; Brandt B; Nesland JM; Pantel K; Naume B
    Breast Cancer Res Treat; 2011 Feb; 125(3):729-38. PubMed ID: 20449649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
    J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse.
    Braun S; Schindlbeck C; Hepp F; Janni W; Kentenich C; Riethmüller G; Pantel K
    J Clin Oncol; 2001 Jan; 19(2):368-75. PubMed ID: 11208828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.
    Bauernhofer T; Zenahlik S; Hofmann G; Balic M; Resel M; Pirchmoser R; Regitnig P; Ambros P; Dandachi N; Samonigg H
    Oncol Rep; 2005 Feb; 13(2):179-84. PubMed ID: 15643496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun S; Pantel K; Müller P; Janni W; Hepp F; Kentenich CR; Gastroph S; Wischnik A; Dimpfl T; Kindermann G; Riethmüller G; Schlimok G
    N Engl J Med; 2000 Feb; 342(8):525-33. PubMed ID: 10684910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis.
    Gaforio JJ; Serrano MJ; Sanchez-Rovira P; Sirvent A; Delgado-Rodriguez M; Campos M; de la Torre N; Algarra I; Dueñas R; Lozano A
    Int J Cancer; 2003 Dec; 107(6):984-90. PubMed ID: 14601059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.
    Janni W; Gastroph S; Hepp F; Kentenich C; Rjosk D; Schindlbeck C; Dimpfl T; Sommer H; Braun S
    Cancer; 2000 May; 88(10):2252-9. PubMed ID: 10820346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
    Xenidis N; Vlachonikolis I; Mavroudis D; Perraki M; Stathopoulou A; Malamos N; Kouroussis C; Kakolyris S; Apostolaki S; Vardakis N; Lianidou E; Georgoulias V
    Ann Oncol; 2003 Jun; 14(6):849-55. PubMed ID: 12796021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.